De-escalation

A large-scale target trial emulation demonstrates that de-escalating anti-MRSA and anti-pseudomonal therapy on day 4 of sepsis treatment is safe, associated with fewer antibiotic days, and leads to shorter hospital stays compared to continuing broad-spectrum regimens.